Tuesday, March 08, 2022 8:38:38 AM
Baudax Bio, Inc.
Tue, March 8, 2022, 5:00 AM·5 min read
In this article:
BXRX
-8.14%
Baudax Bio, Inc.
Baudax Bio, Inc.
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced initiation of a clinical study evaluating the safety and pharmacokinetics (PK) of ANJESO (meloxicam) injection in pediatric patients (ages 2 to <17 years old) following surgery.
https://finance.yahoo.com/news/baudax-bio-initiates-phase-iv-130000680.html
Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?
"We hope not." Richard Dennis
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM